Cephalon — Merger or Acquisition (March 2011)
22 slides from Cephalon's merger presentation, Mar 30, 2011
Slide 1: Valeant's Proposed Acquisition of Cephalon Conference Call
Valeant's Proposed Acquisition of Cephalon Conference Call March 30, 2011
Slide 2: Forward-looking Statements
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company"), including, but not limited to, statements regarding our offer to purchase Cephalon, Inc. ("Cephalon"), financ
Slide 3: Agenda
Agenda Cephalon Key Offer Terms Valeant Overview Cephalon Transaction Timeline - Next Steps
Slide 4: Key Offer Terms
Key Offer Terms $73 per share in cash This represents a 29% premium to Cephalon's 30-day trading average We are willing to consider raising our original offer if Cephalon agrees to let us perform due diligence We will be disciplined on price Debt financing lined up Disciplined approach Intention is
Slide 5: Strategic Rationale
Strategic Rationale Transaction consistent with Valeant strategy We value products, not pipeline Significant opportunities Maximize organic growth and cash flow of in-line specialty pharmaceutical products Enhance European branded generic business Apply Valeant Leveraged R&D model to Cephalon pipeli
Slide 6: Valeant Overview
Valeant Overview Wy VALEANT
Slide 7: Valeant Pharmaceuticals Overview
Valeant Pharmaceuticals Overview Focused, multinational specialty pharma company Specialty Pharma (U.S., Canada, Australia, New Zealand) Dermatology, Neurology and Other Branded Generics - Central Europe (Poland, Serbia, Hungary, Czech Republic) Branded Generics - Latin America (Mexico, Brazil) Dive
Slide 8: Valeant Strategy
Valeant Strategy Truly low cost operating structure Do not bet on science, bet on management Avoid the big guys in the areas where they are strong Do not fall in love with your assets - be willing to sell, partner or shut down Be prudent about investing ahead of need Speed is the greatest advantage
Slide 9: Strong Execution Track Record
Strong Execution Track Record SOURCE: Valeant Valeant Management Team Performance** USD 740% price adjusted increase in companies under current management team (Feb 2008 to today) Consistently exceeded quarterly expectations Total returned to shareholders via repurchases: $850M (shares @ $12.42 aver
Slide 10: Management's Successful M&A Track Record
Management's Successful M&A Track Record Aton Pharma Biovail/Valeant Merger Blaufarma Bunker Cholestagel Coria Labs Delta DermaTech Dow Pharmaceutical Sciences EMO-FARM Hamilton Suncare Laboratories Dr. Renaud PharmaSwiss Private Formula International Reckitt Benckiser Refissa Tecnofarma Ultravate V
Slide 11: Biovail Integration
Biovail Integration Integration largely complete 6 months after closing 500+ employees notified, 400+ employees will have left by the end of Q1 2011 Majority of the facility closures completed R&D progress Relevant programs returned to natural owners for continued development None terminated to date
Slide 12: The Transaction
The Transaction Wy VALEANT
Slide 13: Compelling Value for Cephalon Stockholders
Compelling Value for Cephalon Stockholders Significant premium compared to recent specialty pharma transactions All cash proposal Higher price than share price has traded past 2 years Analysts skeptical that untested management can deliver value First Call consensus stock price target currently $64.
Slide 14: Cephalon's Multiple is Above Peers Factoring in Patent Cliff
Cephalon's Multiple is Above Peers Factoring in Patent Cliff IBES EPS Estimates Price / Earnings * *Share price as of close 28-Mar-2011; Peers include Endo, Forest Laboratories, Salix, Warner Chilcott, Watson
Slide 15: Low Pro Forma Leverage
Low Pro Forma Leverage New debt raised to finance purchase: Cephalon equity $5.7 billion Cephalon converts $1.3 billion Other costs $0.6 billion Less Cephalon cash remaining ($0.9) billion Net = New Debt Raised $6.7 billion Pro Forma Capitalization Current debt $4.5 billion New debt $6.7 billion Tot
Slide 16: Timing is Critical
Timing is Critical Unsustainable set of assets, earnings and cash flow Patent cliffs Generic competition Cephalon spending cash on risky investments Recent deals - Gemin X and ChemGenex Development pipeline Continued investment in infrastructure No cost cutting in place "...when Provigil goes away,
Slide 17: Research Analysts Say Cephalon's "Lottery" Strategy is Misguided
Research Analysts says Cephalon's "Lottery" Strategy is Misguided "Despite our assertion that the market is well aware that Cephalon earnings will decline, we do not argue the stock have reached a floor. ...while the pipeline lottery cards are keeping us away from suggesting shorting the stock, they
Slide 18: No Substantive Engagement by Cephalon's Board
No Substantive Engagement by Cephalon's Board Original offer on March 18 $73 per share all cash proposal Cephalon response: Well below where we would consider selling, but Board will meet...analysts and investors are obsessed with our patent cliffs and don't give us enough credit for our pipeline po
Slide 19: Transaction Process
Transaction Process Appealing directly to shareholders due to lack of engagement by Cephalon's Board of Directors Prepared to engage in consensual negotiations at any time Intend to promptly commence Consent Solicitation Process during week of April 4 to replace Cephalon's Board of Directors: Notify
Slide 20: Valeant's Transaction Operating Principles
Valeant's Transaction Operating Principles Our primary objective is shareholder value We do not enter a transaction to win at all costs We are dispassionate in any single deal We do not play games in negotiations or participate in auctions We maximize speed and believe "deal process" creates distrac
Slide 21: What We Ask from Cephalon Stockholders
What We Ask from Cephalon Stockholders After record date, let your Board know your vote quickly If we have a majority vote, we will move forward quickly - if not, we will move on Friendly Offer to Owners of Cephalon Certain - all cash (potentially higher after due diligence) Immediate - not dependen
Slide 22: Valeant's Proposed Acquisition of Cephalon Conference Call
Valeant's Proposed Acquisition of Cephalon Conference Call March 30, 2011